76041-06-0

Upstream product

• 632352-54-6 3-[benzyl-(2-ethoxycarbonyl-ethyl)-amino]-2-phenyl-propionic acid ethy ester 
• 4244-84-2 ethyl β-alaninate hydrochloride 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 101-97-3 Ethyl 2-phenylethanoate 
• 22286-82-4 2-phenyl-acrylic acid ethyl ester 
• 22319-48-8 ethyl 2-phenyl-3-(N-benzylamino)propionate 
• 140-29-4 phenylacetonitrile 
• 4553-07-5 ethyl phenylcyanoacetate 
• 135959-07-8 α-(aminomethyl)benzeneacetic acid,ethyl ester 
• 140-88-5 ethyl acrylate 

Downstream Products

• 632352-54-6 3-[benzyl-(2-ethoxycarbonyl-ethyl)-amino]-2-phenyl-propionic acid ethy ester 
• 910875-38-6 ethyl 3-(2-ethoxycarbonylethylamino)-2-phenylpropionate phosphate 
• 1096168-16-9 4-oxo-5-phenyl-piperidine-3-carboxylic acid ethyl ester 
• 1263870-17-2 ethyl 3-((3-ethoxy-3-oxopropyl)(4-methoxybenzyl)amino)-2-phenylpropanoate 
• 76040-33-0 ethyl 3-((3-ethoxy-3-oxopropyl)(methyl)amino)-2-(phenyl)propanoate 
• 92652-75-0 ethyl 1-methyl-4-oxo-5-phenylpiperidine-3-carboxylate 
• 1263870-18-3 ethyl 1-(4-methoxybenzyl)-4-oxo-5-phenylpiperidine-3-carboxylate 
• 1263870-37-6 6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2,4(1H,3H)-dione 
• 1263870-36-5 2,4-dichloro-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 
• 1263870-38-7 2-chloro-N,6-dimethyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1263870-39-8 2-chloro-N-ethyl-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-amine 
• 1384264-55-4 C₂₁H₂₃NO₃ 
• 76041-09-3 3-phenyl-4-piperidone 
• 1096168-17-0 3-phenyl-5-[1-pyridin-2-yl-methylidene]-piperidin-4-one 

Relevant academic research and scientific papers

COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

The present disclosure provides a series of compounds of the formula (I), which modulate β-amyloid peptide (β-ΑΡ) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-ΑΡ) production.

Design, structure-activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists

We synthesized a series of novel 3-phenyl-4-benzylaminopiperidine derivatives that were identified as potent tachykinin NK1 receptor antagonists by structural modification of the 3-benzhydrylpiperidone derivative through high-throughput screening. N-{2-[(3R,4S)-4-({2-Methoxy-5-[5-(trifluoromethyl)- 1Htetrazol-1-yl]benzyl}amino)-3-phenyl-1-piperidinyl]-2-oxoethyl}acetamide ((+)-39) was found to be one of the most potent tachykinin NK1 receptor antagonists with high metabolic stability. Highly efficient asymmetric synthesis of (+)-39 was achieved via dynamic kinetic resolution.

COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION

The present disclosure provides a series of compounds of the formula (I) which modulate β-amyloid peptide (β-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-AP) production.

NOVEL SUBSTITUTED PIPERIDONES AS HSP INDUCERS

The present invention relates to novel compounds of formula (I) or (II), their pharmaceutically acceptable salts and their hydrates, solvates, stereoisomers, conformers, tautomers, polymorphs and prodrugs and also pharmaceutically acceptable compositions containing them Wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification. The compounds of the present invention are HSP inducers and by virtue of this effect, useful for the treatment of various diseases accompanying pathological stress. The present invention also relates to a process for the preparation of the said novel compounds. The invention also relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.

Piperidine derivative crystal, process for producing the same, and use

The present invention provides a piperidine derivative having antagonistic action for tachykinin receptors and the like, a crystal thereof, and an agent for the prophylaxis or treatment of diseases including lower urinary tract disease and the like, which contains the derivative. Specifically, the present invention provides an optically active compound represented by the formula (I): wherein each symbol is as defined in the specification, and a salt thereof.